- Home
- GERN vs BBNX Comparison
GERN vs BBNX Comparison
Compare GERN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- BBNX
- Stock Information
- Founded
- GERN 1990
- BBNX 2015
- Country
- GERN United States
- BBNX United States
- Employees
- GERN N/A
- BBNX N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- GERN Health Care
- BBNX Health Care
- Exchange
- GERN Nasdaq
- BBNX Nasdaq
- Market Cap
- GERN 700.6M
- BBNX 578.8M
- IPO Year
- GERN 1996
- BBNX 2025
- Fundamental
- Price
- GERN $1.17
- BBNX $16.40
- Analyst Decision
- GERN Buy
- BBNX Strong Buy
- Analyst Count
- GERN 8
- BBNX 10
- Target Price
- GERN $3.71
- BBNX $24.40
- AVG Volume (30 Days)
- GERN 9.2M
- BBNX 553.4K
- Earning Date
- GERN 08-06-2025
- BBNX 07-29-2025
- Dividend Yield
- GERN N/A
- BBNX N/A
- EPS Growth
- GERN N/A
- BBNX N/A
- EPS
- GERN N/A
- BBNX N/A
- Revenue
- GERN $116,293,000.00
- BBNX $69,830,000.00
- Revenue This Year
- GERN $161.44
- BBNX $32.71
- Revenue Next Year
- GERN $53.06
- BBNX $37.37
- P/E Ratio
- GERN N/A
- BBNX N/A
- Revenue Growth
- GERN 22264.04
- BBNX 38911.17
- 52 Week Low
- GERN $1.09
- BBNX $8.89
- 52 Week High
- GERN $4.89
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- GERN 39.34
- BBNX N/A
- Support Level
- GERN $1.20
- BBNX N/A
- Resistance Level
- GERN $1.37
- BBNX N/A
- Average True Range (ATR)
- GERN 0.08
- BBNX 0.00
- MACD
- GERN -0.01
- BBNX 0.00
- Stochastic Oscillator
- GERN 28.57
- BBNX 0.00
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.